idiopathic pulmonary fibrosis
PulseAugur coverage of idiopathic pulmonary fibrosis — every cluster mentioning idiopathic pulmonary fibrosis across labs, papers, and developer communities, ranked by signal.
-
AI-designed drug reverses biological aging markers in early trial
Insilico Medicine's AI-designed drug, INS018_055, has shown promising results in a phase I clinical trial for idiopathic pulmonary fibrosis. The drug, rentosertib, appears to reverse biological aging markers, with six i…
-
AI accelerates idiopathic pulmonary fibrosis drug discovery timeline
AI played a significant role in the development of Rentosertib, a drug targeting idiopathic pulmonary fibrosis. The AI system identified TNIK as a novel target and optimized the molecular structure, compressing the disc…
-
Insilico Medicine advances AI-discovered drug rentosertib to Phase III trials for IPF
Insilico Medicine is moving its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis (IPF). The drug, which targets the TNIK protein, showed promising results in Phase II tri…